Genta Incorporated to Present at Raymond James Annual Institutional Investors Conference
BERKELEY HEIGHTS, N.J., Feb 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) today announced its participation at the Raymond
James & Associates' 24th Annual Institutional Investors Conference in Orlando,
Florida. Tara Spiess, Genta's Director of Investor Relations and Corporate
Communications, will provide an update on the Company's pipeline and
registration trials on Tuesday, March 4, 2003 at 8:05 a.m. EST.
A live audio webcast of the presentation can be accessed through Genta's
Investor Relations site at: genta.com. A replay will be
available for 30 days following the presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on anticancer therapy. The Company's research platform
is anchored by oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. Genasense(TM), the Company's lead compound, is
being developed in collaboration with Aventis and is currently undergoing
late-stage, Phase 3 clinical testing in several clinical indications. Genta's
pipeline also comprises a portfolio of small molecules, including
gallium-containing compounds and Androgenics compounds for prostate cancer, as
well as an anticancer series of DNA-based compounds called "decoy aptamers." For
more information about Genta, please visit our website at: genta.com. |
